2023
Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure
Fuery M, Kadhim B, Samsky M, Freeman J, Clark K, Desai N, Wilson F, Ahmed T, Ahmad T. Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure. Current Heart Failure Reports 2023, 20: 280-286. PMID: 37552356, DOI: 10.1007/s11897-023-00614-0.Peer-Reviewed Original ResearchConceptsHeart failure patientsFailure patientsElectronic health recordsEHR alertClinical trialsRandomized clinical trialsCare of patientsQuality of careHeart failureClinician satisfactionRandomized fashionRecent FindingsTherePatientsUnmet needPatient careClinical decisionEvidence-based decisionsFuture interventionsCareHealth recordsTrialsCliniciansInterventionFindingsThereHyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon
Teaw S, Gupta A, Williams A, Wilson F, Sumpio B, Sumpio B, Hinchcliff M. Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon. Arthritis Research & Therapy 2023, 25: 10. PMID: 36670487, PMCID: PMC9854186, DOI: 10.1186/s13075-023-02990-3.Peer-Reviewed Original ResearchConceptsRaynaud's condition scoreCochin Hand Function ScaleSSc patientsClinic settingPatient-reported outcome instrumentsResultsNinety-two percentSystemic sclerosis patientsMann-Whitney U testHealthy control participantsCHF scoreSSc durationSSc-RPDigital ulcersCutaneous SScProvocation challengeRaynaud's phenomenonSclerosis patientsClinical trialsOutcome instrumentsOxygen saturationBurden assessmentPatientsCold provocationHemoglobin concentrationDisease severity
2022
Optimizing the Design and Analysis of Future AKI Trials
Legrand M, Bagshaw SM, Koyner JL, Schulman IH, Mathis MR, Bernholz J, Coca S, Gallagher M, Gaudry S, Liu KD, Mehta RL, Pirracchio R, Ryan A, Steubl D, Stockbridge N, Erlandsson F, Turan A, Wilson FP, Zarbock A, Bokoch MP, Casey JD, Rossignol P, Harhay MO. Optimizing the Design and Analysis of Future AKI Trials. Journal Of The American Society Of Nephrology 2022, 33: 1459-1470. PMID: 35831022, PMCID: PMC9342638, DOI: 10.1681/asn.2021121605.Peer-Reviewed Original ResearchConceptsAKI trialsClinical trialsTrial participantsTrial designAKI clinical trialsPerioperative patient populationsComplex clinical syndromeRisk of morbidityPragmatic trial designTreatment effectsClinical trial planningImportant treatment effectsClinical trial analysisAKI preventionClinical courseClinical syndromePatient populationTrial interventionClinical questionsClinical trialistsAKITrial infrastructureTrial planningTrialsEfficient enrollment
2021
Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis
Chandrasekaran AC, Fu Z, Kraniski R, Wilson FP, Teaw S, Cheng M, Wang A, Ren S, Omar IM, Hinchcliff ME. Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis. Arthritis Research & Therapy 2021, 23: 6. PMID: 33407814, PMCID: PMC7788847, DOI: 10.1186/s13075-020-02392-9.Peer-Reviewed Original ResearchConceptsSSc patientsCalcinosis cutisCC lesionsSystemic sclerosisBland-Altman plotsConcordance correlation coefficientIndependent radiologistsLin's concordance correlation coefficientConfidence intervalsValid clinical trialsExpert musculoskeletal radiologistsSpearman correlation coefficientClinical trialsMusculoskeletal radiologistsPatientsBurden quantificationLesionsMean differenceGold standardRadiologistsCorrelation coefficientLonger lengthPhalanxSpearman's rhoValidation study
2020
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete data
2019
Clinical Implications of the New York Heart Association Classification
Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM, Piña IL, O'Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical Implications of the New York Heart Association Classification. Journal Of The American Heart Association 2019, 8: e014240. PMID: 31771438, PMCID: PMC6912957, DOI: 10.1161/jaha.119.014240.Peer-Reviewed Original ResearchConceptsNew York Heart Association classificationHF clinical trialsNYHA class IIVentricular ejection fractionGUIDE-ITHeart failureNYHA classWalk distanceEjection fractionRisk stratificationHF-ACTIONAssociation classificationClinical trialsMinute ventilation-carbon dioxide production relationshipKansas City Cardiomyopathy Questionnaire scoreClass IIMulticenter National InstituteNYHA class IIINT-proBNP levelsKaplan-Meier curvesLog-rank testClinical trial eligibilityWilcoxon rank sum testMaximal oxygen uptakeRank sum testPatient-Reported Outcome Measures for Adults With Kidney Disease: Current Measures, Ongoing Initiatives, and Future Opportunities for Incorporation Into Patient-Centered Kidney Care
Nair D, Wilson FP. Patient-Reported Outcome Measures for Adults With Kidney Disease: Current Measures, Ongoing Initiatives, and Future Opportunities for Incorporation Into Patient-Centered Kidney Care. American Journal Of Kidney Diseases 2019, 74: 791-802. PMID: 31492487, PMCID: PMC6875620, DOI: 10.1053/j.ajkd.2019.05.025.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPatient-reported outcome measuresHealth care policyKidney diseaseClinical trialsOutcome measuresClinical careCare policyPerception of diseaseLaboratory markersPatient's symptomsKidney carePatient experienceNephrology communityPatient voiceNarrative overviewDiseaseCareSymptomsTrialsAdultsOngoing initiativesNephrologistsPatientsClinicians
2017
Evaluating biomarkers for prognostic enrichment of clinical trials
Kerr KF, Roth J, Zhu K, Thiessen-Philbrook H, Meisner A, Wilson FP, Coca S, Parikh CR. Evaluating biomarkers for prognostic enrichment of clinical trials. Clinical Trials 2017, 14: 629-638. PMID: 28795578, PMCID: PMC5714681, DOI: 10.1177/1740774517723588.Peer-Reviewed Original ResearchConceptsPrognostic enrichmentTrial eligibility criteriaClinical trialsEligibility criteriaTrial resultsClinical trial sample sizesOutcomes of interestTrial sample sizeTrial metricsOnly patientsBACKGROUND/Prognostic biomarkerPrognostic performanceHigh riskClinical settingScreening costsBiomarkersTrialsScreening thresholdCalendar timeTrial costsSample sizePatients
2016
Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial
Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, Tang WH, Testani JM. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. Journal Of Cardiac Failure 2016, 22: 753-760. PMID: 27374839, PMCID: PMC5435117, DOI: 10.1016/j.cardfail.2016.06.423.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCause of DeathCreatinineDisease ProgressionDisease-Free SurvivalDiureticsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFurosemideGlomerular Filtration RateHeart FailureHumansInfusions, IntravenousKidney Function TestsMaleMiddle AgedPrognosisSurvival RateTreatment OutcomeConceptsStable renal functionRenal functionComposite endpointDecongestive strategiesSerum creatinineDose trialAdverse outcomesClinical trialsSurrogate endpointsDiuretic Optimization Strategies Evaluation (DOSE) trialHeart failure clinical trialsHeart Failure TrialPoor prognostic signCoprimary endpointsComposite outcomeDecongestive therapyFailure TrialPrognostic signEmergency roomImproved outcomesLower riskCreatinineEndpointTrialsAbsence of risk
2014
A trial of in-hospital, electronic alerts for acute kidney injury: Design and rationale
Wilson FP, Reese PP, Shashaty MG, Ellenberg SS, Gitelman Y, Bansal AD, Urbani R, Feldman HI, Fuchs B. A trial of in-hospital, electronic alerts for acute kidney injury: Design and rationale. Clinical Trials 2014, 11: 521-529. PMID: 25023200, PMCID: PMC4156885, DOI: 10.1177/1740774514542619.Peer-Reviewed Original ResearchConceptsAcute kidney injuryKidney injuryElectronic alert systemHospitalized patientsElectronic alertsInformed consentStage 1 acute kidney injuryStage 3 acute kidney injuryAcute kidney injury severityStudy outcomesAcute kidney injury alertsLow-risk interventionBroad inclusion criteriaInpatient mortalitySerum creatinineMedical recordsClinical trialsPatient outcomesInclusion criteriaProvider recognitionEarly deathDichotomous outcomesInjury severityPatientsInjury